Akero Therapeutics' EFX Data Warrants Caution [Seeking Alpha]
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
In our view, Efruxifermin's phase 2 data reveal a fragile efficacy profile and a concerning safety record, casting doubt on its potential to successfully translate into phase 3 trials. MASH space growing competition and future sales of Resmetirom will significantly impact valuations. Introduction And Investment Thesis Thesis This analysis posits Akero Therapeutics, Inc. ( NASDAQ: AKRO ) as a potential short investment, premised on the assessment that its flagship product, Efruxifermin (EFX) - an FGF21 analogue - faces considerable hurdles toward achieving substantial market success. The likelihood of FDA approval appears constrained, not merely by the drug's marginal efficacy but also due to concerns over bone mass density (BMD) implications and adverse quality of life (QoL) impacts. In our opinion, the methodology employed by Akero in their statistical analysis paints an overly favorable clinical relevance, therefore making the underlying fragility of the data less apparent.
Show less
Read more
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc.Business Wire
- AKRO INVESTOR ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action -AKROPR Newswire
- DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero TherapeuticsPR Newswire
- DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Akero Therapeutics, Inc.with Losses to Contact the FirmAccesswire
- Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer [Yahoo! Finance]Yahoo! Finance
AKRO
Earnings
- 11/13/23 - Miss
AKRO
Analyst Actions
- 3/5/24 - UBS
AKRO
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- 4/16/24 - Form PRE
- AKRO's page on the SEC website